ARS Pharmaceuticals, Inc. (SPRY) Operating income 2020–2025
ARS Pharmaceuticals, Inc. (SPRY) annual operating income history from SEC filings — each fiscal year as reported.
-$179.4MFY2025 · since FY2020: -$32.9M → -$179.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$179.4M | -5720.6% |
| FY2024 | -$3.1M | +95.4% |
| FY2023 | -$67.5M | -90.1% |
| FY2022 | -$35.5M | -82.6% |
| FY2021 | -$19.5M | +40.9% |
| FY2020 | -$32.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRY financial trends
SPRY RevenueSPRY Net incomeSPRY Net marginSPRY Gross profitSPRY Gross marginSPRY Operating marginSPRY Operating cash flowSPRY Free cash flowSPRY Capital expendituresSPRY Return on equitySPRY Stock buybacksSPRY Dividends paidSPRY Total assetsSPRY Total liabilitiesSPRY Shareholders’ equitySPRY overview →